Mercer Global Advisors
TVTX icon

Mercer Global Advisors’s Travere Therapeutics TVTX Stock Holding History

Mercer Global Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
7,218
-54
-0.7% -$1.61K ﹤0.01% 2773
2025
Q4 		$278K Buy
+7,272
New +$236K ﹤0.01% 2298
2020
Q2 		– Sell
-14,527
Closed -$212K – 1172
2020
Q1 		$212K Sell
14,527
-4,535
-24% -$68.2K ﹤0.01% 920
2019
Q4 		$271K Buy
19,062
+2,652
+16% +$33.9K 0.01% 957
2019
Q3 		$190K Buy
16,410
+1,639
+11% +$27.1K ﹤0.01% 1041
2019
Q2 		$297K Buy
14,771
+341
+2% +$6.73K 0.01% 881
2019
Q1 		$327K Buy
+14,430
New +$319K 0.01% 789

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mercer Global Advisors's TVTX Position: Q1 2026 in Review

Mercer Global Advisors reduced its Travere Therapeutics (TVTX) stake by 0.74% in Q1 2026, selling an estimated $1.61K and leaving 7,218 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

Mercer Global Advisors first reported a position in TVTX in Q1 2019 and has held it in 7 quarters since. The position peaked at $327K in Q1 2019. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Mercer Global Advisors held 7,218 shares of Travere Therapeutics worth $214K as of Q1 2026.
  • Mercer Global Advisors sold 54 Travere Therapeutics shares in Q1 2026, an estimated $1.61K.
  • Travere Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2773 holding.
  • Mercer Global Advisors first reported a position in Travere Therapeutics in Q1 2019 and has held it in 7 quarters since.
  • Mercer Global Advisors's Travere Therapeutics position peaked at $327K in Q1 2019.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.